EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients

NCT01942005 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2014-12-04

No results posted yet for this study

Summary

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Conditions

Sponsors & Collaborators

  • Andreas Arnold

    lead OTHER

Principal Investigators

  • Andreas Arnold, MD · University Hospital Basel, Dermatology, CH-4031 Basel

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01942005 on ClinicalTrials.gov